ImageneBio (IMA) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on innovative therapies for autoimmune, immunological, and inflammatory (I&I) diseases.

• Lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody targeting activated T cells, initially for atopic dermatitis (AD), with potential expansion to other I&I indications.

• IMG-007 is exclusively licensed from Hutchmed; manufacturing is outsourced to WuXi Biologics.

• Completed a merger with Ikena Oncology, Inc., resulting in a reverse recapitalization and rebranding as ImageneBio, Inc.

Financial performance and metrics

• Net loss of $13.7 million for the six months ended June 30, 2025, and $36.6 million for the year ended December 31, 2024.

• Accumulated deficit of $197.5 million as of June 30, 2025.

• Cash and cash equivalents of $6.0 million as of June 30, 2025, prior to merger-related financing.

• No revenue from product sales; revenue to date derived from licensing agreements.

Use of proceeds and capital allocation

• Proceeds from the PIPE Financing ($75 million) are intended for advancing the clinical pipeline, business development, working capital, and general corporate purposes.

• Company will not receive proceeds from the resale of shares by selling stockholders; all registration expenses are paid by the company.